Cardiac Disease, Congenital Heart Disease, Cyanotic Congenital Heart Disease, Hypoplastic Left Heart
Conditions
Keywords
Troponin, BNP, Biomarkers, Hypoplastic Left Heart, Norwood, DKS
Brief summary
All neonates with congenital heart disease undergoing stage one palliation (Norwood procedure, Damus-Kaye-Stansel procedure) at Texas Children's Hospital will be regularly monitored for B-type natriuretic peptide (BNP) and Troponin level before the surgical procedure, on arrival to the cardiac intensive care unit after their surgical procedure, every 6 hours during the first 24 hours of the post-operative period, followed by daily levels for the first week, and then weekly during patient's regular laboratory work up schedule. These cardiac biomarkers are linked to demographic, hemodynamic, respiratory, pharmacological data available via Sickbay.
Detailed description
All neonates with congenital heart disease undergoing stage one palliation (Norwood procedure, Damus-Kaye-Stansel procedure) at Texas Children's Hospital will be regularly monitored for B-type natriuretic peptide (BNP) and Troponin level before the surgical procedure, on arrival to the cardiac intensive care unit after their surgical procedure, every 6 hours during the first 24 hours of the post-operative period, followed by daily levels for the first week, and then weekly during patient's regular laboratory work up schedule. These cardiac biomarkers are linked to demographic, hemodynamic, respiratory, pharmacological data available via Sickbay.
Interventions
PROCEDURENorwood Palliation / DKS / Damus-Kaye-Stansel procedure
Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
Sponsors
Baylor College of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 2 Months
Healthy volunteers
No
Inclusion criteria
Clinical diagnosis of Hypoplastic Left Heart Syndrome as congenital heart disease as a neonate
Exclusion criteria
Other diagnosis of congenital heart disease than Hypoplastic Left Heart Syndrome Patients older than 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 3- 6 months depending on second stage procedure | Mortality up to anticipated Glenn Procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NEC | 3- 6 months depending on second stage procedure | Incidence of Necrotizing enterocolitis |
| Reintubation | 3- 6 months depending on second stage procedure | Incidence of Reintubation |
| Cath intervention | 3- 6 months depending on second stage procedure | Incidence of cath interventions |
Countries
United States
Outcome results
None listed